Three new acylphloroglucinol glycosides, hypericumols A -C, together with fifteen known phenolic derivatives, were isolated from the total phenolic extract of Hypericum japonicum. Hypericumols A, B, and C were characterized as 4,6-dimethyl-2-methylpropanoylphloroglucinol-1-O-β-D-glucopyranoside (1), 4-methyl-2-methylpropanoylphloroglucinol-1-O-β-D-glucopyranoside (2), and (2S)-4,6-dimethyl-2-methylbutyrylphloroglucinol-1-O-β-D-glucopyranoside (3), respectively, on the basis of spectroscopic data interpretation and chemical degradation reaction.
Hypericum japonicum Thunb., di er cao or tian ji huang in Chinese, is an annual / perennial herbal plant [1] . It is widely distributed in Asia, Oceania, and North America [1] . The whole plant material has been used in traditional Chinese medicine for heat-relieving, detoxification, hemostasis, and detumescence [1] . Phytochemical and pharmacological investigations showed that the chemical components of H. japonicum have diverse biological activities such as antioxidant [2], antivirus [3] , antitumor [4] , antimicrobial [5] , and hepatoprotection [2a, 6] . Flavonoids and chromones are the primary chemical components of H. japonicum, whereas phloroglucinols and xanthones are two characteristic metabolites present in H. japonicum [7] . Recent studies demonstrated that the total phenolic extract of H. japonicum showed potential application to cure chronic kidney disease (CKD), which may be attributed to its effects on interfering with renal fibrosis, and enhancing cellular and humoral immunity [8] . As part of our continuing interests in the chemistry of traditional Chinese medicines [9], here we report the isolation and structure characterization of three new acylphloroglucinol glycosides (1 -3), together with fifteen known compounds, including an acylphloroglucinol (4), nine flavonoids (5 -12, 16), three benzoic acid derivatives (13 -15), a pyrone (17) , and a chromone glycoside (18) , from the phenolic extract of H. japonicum (Figure 1 ).
Compound 1 was isolated as a yellowish gum. Its molecular formula C 18 H 26 O 9 was calculated from the [M+Na] + ion at m/z 409.1480 in its HRESIMS (positive ion mode). The hydroxyl and conjugated carbonyl groups were deduced from the IR bands at 3410 and 1615 cm -1 , respectively. Besides the 1 H NMR signals for a hexose moiety, two singlet methyls at  H = 2.03 (3H, s) and 2.20 (3H, s), two doublet methyls at  H = 0.99 (3H, d, J = 6.9 Hz) and 1.16 (3H, d, J = 6.9 Hz), and a heptet methine group at  H = 4.05 (1H, h, J = 6.9 Hz) were recognized from the 1 H NMR spectrum (Table 1 ). In addition to the 13 C NMR signals for the groups mentioned above, seven downfield quaternary carbon signals ( C > 109) were observed in the 13 C NMR spectrum (Table 1) , which indicated the presence of a phenyl and a conjugated keto carbonyl group. Compound 1 might be an acylphloroglucinol derivative in view of its characteristic UV bands at 290 and 329 nm for acylphloroglucinol [10] . A 2-methyl propionyl group was established from the two doublet methyls, the heptet methine, and the keto carbonyl group on the basis of 1 H-1 H COSY correlations of H-3 / H-2 / H-2-CH 3 and the key HMBC correlations of H-2 / C-1, C-3, C-2-CH 3 ; H-3 / C-1, C-2-CH 3 ; and H-2-CH 3 / C-1 shown in Figure 2 . A 2,4-dimethyl-1,3,5trihydroxyphenyl moiety was established from the key HMBC correlations of H-4-CH 3 / C-3, C-4, C-5 and H-6-CH 3 / C-1, C-5, C-6 ( Figure 2 ). Acid hydrolysis of compound 1 afforded an acylphloroglucinol and D-glucose with β-orientation in view of the 1 H NMR signal of the anomeric proton at  H = 4.38 (1H, d, J = 7.7 Hz). The 1-OH was glucosylated in view of the key HMBC correlation of H-1 / C-1 ( Figure 2 ). Thus compound 1, named as hypericumol A, was characterized as 4,6-dimethyl-2methylpropanoylphloroglucinol-1-O-β-D-glucopyranoside ( Figure  1 ). Compound 2 showed similar IR and UV bands to that of compound 1, which suggested that 2 might be an acylphloroglucinol derivative. The molecular formula of 2 was determined to be C 17 H 24 O 9 from the [M+Na] + ion at m/z 395.1305 from the HRESIMS (positive ion mode). Comparison of the NMR data of compound 2 with that of compound 1 ( Table 1) showed that a singlet methyl group of 1 was replaced by an aromatic proton at  H = 6.23 (1H, s) to form 2, which was consistent with the molecular formula of 2. As shown in Figure 2 , the spectroscopic data interpretation confirmed that the 6-methyl of 1 was replaced by the proton mentioned above to form 2. Thus compound 2, named as hypericumol B, was characterized as 4-methyl-2-methyl propanoylphloroglucinol-1-O-β-D-glucopyranoside ( Figure 1 ).
Compound 3 had similar spectroscopic characteristics to that of compounds 1 and 2. The molecular formula of 3, C 19 H 28 O 9 , was determined from the [M+Na] + ion at m/z 423.1614 in its HRESIMS (positive ion mode). This indicated an additional CH 2 group present in the structure of 3, relative to that of 1. Comparison of the NMR signals of 3 with those of 1 showed that a doublet methyl of 1 was replaced by a triplet methyl at  H = 0.97 (3H, t, J = 7.5 Hz) in 3. A CH 2 group at  H = 1.90 (1H, m) and 1.41 (1H, m) /  C = 25.94 was deduced from the NMR spectroscopic data (Table 1) and it was confirmed to be adjacent to the triplet methyl group by the 1 H-1 H COSY and HMBC correlations ( Figure 2) . A 2-methylbutyryl group was established from a doublet methyl, a triplet methyl, a methine, a methylene, and a keto carbonyl group on the basis of detailed spectroscopic data interpretation (Figure 2 ). Acid hydrolysis of 3 led to the identification of D-glucose and 4,6-dimethylmultifidol (3a) [11] . The absolute configuration of C-2 in 3a was determined to be S by its optical rotation ([α] D 20 +2.4), according to the empirical rule established by Pei et al. to determine the absolute configuration of 2-methylbutyrylphloroglucinols [12] . Thus, the structure of compound 3 was elucidated as (2S)-4,6-dimethyl-2methylbutyrylphloroglucinol-1-O-β-D-glucopyranoside. Compound 3 was a product of the acid hydrolysis of 4,6-dimethyl-1-O-[-Lrhamnopyranosyl-(16)-β-D-glucopyranosyl]multifidol [13] . However, no spectroscopic data were reported and assigned to the product [13] . Here we report the compound as a naturally occurring product from the plant with detail spectroscopic data and named it as hypericumol C (3) (Figure 1 ).
The known compounds isolated from the phenolic extract were identified as 2-(2-methylpropionyl)-4-methylphloroglucinol (4) [14] , quercetin (5) [15] , 3-O-methylquercetin (6) [16] , isoquercitrin (7) [17], quercetin-7-O-α-L-rhamnopyranoside (8) [18] , kaempferol-7-O-α-L-rhamnopyranoside (9) [19] , dihydroquercetin (10) [2c], dihydrokaempferol-7-O-α-L-rhamnopyranoside (11) [20], (2R,3R)-taxifolin-7-O-α-L-rhamnopyranoside (12) [21] , phydroxybenzoic acid (13) [22] , ethyl 3,4-dihydroxybenzoate (14) [23] , ethyl 2,4,6-trihydroxybenzoate (15) [24] , epicatechin (16) [25] , saropyrone (17) [26] , and 5,7-dihydroxy-2-(1-methylpropyl) chromone-8-β-D-glucopyranoside (18) [27] on the basis of spectroscopic analyses.
In summary, three new acylphloroglucinol glycosides and fifteen known phenolic natural products were isolated and identified from the phenolic extract of H. japonicum. Among them, quercetin (5), isoquercitrin (7) , and dihydroquercetin (10) are the major chemical components of the extract. Quercetin (5) has been reported to recover renal amyloidosis and collagen deposition [28] and exhibit anti-fibrotic and kidney protection activities related to renal dysfunction [29], indicating its therapeutic potential in treating CKD. Meanwhile, oxidative stress induced by free radicals play a vital role in the progression of kidney diseases such as renal fibrosis and chronic renal failure [30] , which suggested that antioxidant therapy using phenolic derivatives might be a practical strategy for CKD. The chemical investigations presented here support, in part, the potent application of the phenolic extract of H. japonicum in the treatment of CKD.
Experimental
General: Optical rotations were recorded on a Perkin-Elmer 341 automatic polarimeter. UV-Vis spectra were collected on a Perkin-Elmer Lambda 35 UV-Vis spectrometer with λ max given in nanometers. IR spectra were recorded on a Perkin-Elmer Spectrum One spectrometer with ν max given in cm -1 . NMR spectra were recorded on a Bruker Ascend 400 spectrometer with chemical shifts  in ppm. HRESIMS were measured on a Bruker Bio TOF IIIQ (quadrupole time of flight) mass spectrometer and ESIMS on a Waters Xevo TQ (tandem quadrupole) mass spectrometer. Column chromatography (CC) was performed on silica gel (Qindao Haiyang Chemical Co., Ltd., P. R. China (QHCC)), silica gel 60 (Merck, German), ODS gel (YMC Co., Ltd, Japan), or Sephadex LH-20 (GE Healthcare Bio-Sciences AB, Sweden). Thin layer chromatography (TLC) was conducted on plates precoated with 10 -40 μm of silica gel GF254 from QHCC. Preparative HPLC separation was carried out on a LC3000 liquid chromatograph (Beijing Chuangxin Tongheng Science and Technology Co., Ltd) with a YMC C 18 column (20 × 250 mm; 10 μm), and semi-preparative HPLC on a Perkin-Elmer 200 liquid chromatograph with a Welch C 18 column (10 × 250 mm; 5 μm), and detected at 208 nm. All solvents were Phenolic compounds from Hypericum japonicum Natural Product Communications Vol. 10 (12) 2015 2111 commercially purchased and distilled under normal atmospheric pressure prior to use.
Extraction and isolation:
The crude phenolic extract was provided by Chengdu Nanshan Pharmaceutical Co., Ltd. The crude extract was prepared, according to the following procedure. The whole plant material of H. japonicum was air-dried and extracted with 65% aqueous EtOH with refluxing. The filtrates were concentrated to remove EtOH under reduced pressure. The aqueous residue was subjected to CC on HPD100 macroporous resin eluted with H 2 O, 30% and 80% EtOH, respectively. The eluents of 80% EtOH were collected and concentrated to afford the crude phenolic extract. This (350 g) was separated by CC over silica gel (160-200 mesh) eluted with light petroleum-acetone (2:1, 1:1, 0:1; v/v) to afford 15 subfractions S1 -S15. Fraction S3 (3.9 g) was subjected to preparative HPLC eluted with CH 3 OH-H 2 O (60:40, v/v; 15 mL/min) to give compound 14 (t R = 7.6 min; 23 mg) and three sub-fractions S3B -S3D. Fraction S3B was purified with semi-preparative HPLC with CH 3 CN-H 2 O (31:69, v/v; 5 mL/min) as eluents to afford compound 15 (t R = 30 min; 6 mg). Fraction S3D was separated by semipreparative HPLC eluted with CH 3 CN-H 2 O (31:69, v/v; 5 mL/min) to afford compound 4 (t R = 32 min; 70 mg). Fraction S4 was separated by preparative HPLC eluted with CH 3 OH-H 2 O (54:46, v/v; 20 mL/min) to give compounds 6 (t R = 30 min; 60 mg) and 17 (t R = 32 min; 6 mg), and four sub-fractions S4A -S4D. Fraction S4A was separated by semi-preparative HPLC eluted with CH 3 OH-H 2 O (38:62, v/v; 4 mL/min) to afford a sub-fraction S4A1 (t R = 8 min) that was then subjected to CC on silica gel 60 (15 -40 m) eluted with CHCl 3 -MeOH (10:1, v/v) to afford compound 13 (2 mg). Compound 5 (9.4 g) was precipitated from the light petroleumacetone (2:1) solution of fraction S6. Compound 10 (3.8 g) was precipitated from the light petroleum-acetone (2:1) solution of fraction S7. The remaining sub-fraction of S7 was separated by CC over silica gel (160-200 mesh) with CHCl 3 -MeOH (15:1, v/v) as solvent to give 4 sub-fractions S7A -S7D. Fraction S7B was subjected to preparative HPLC eluted with CH 3 OH-H 2 O (50:50, v/v; 15 mL/min) to afford compound 3 (t R = 29 min; 63 mg) and 3 sub-fractions S7B1 -S7B3. Fraction S7B3 was separated by semipreparative HPLC eluted with CH 3 OH-H 2 O (50:50, v/v; 3 mL/min) to afford subfraction S7B3C (t R = 20 min) that was subjected to semi-preparative HPLC eluted with CH 3 CN-H 2 O (32:68, v/v; 3 mL/min) to give compounds 1 (t R = 11 min; 463 mg) and 2 (t R = 26 min; 6 mg). Compound 8 (88 mg) was crystallized from the methanol solution of fraction S9. Fraction S10 was separated over a self-packed ODS column using CH 3 OH-H 2 O (40:60, v/v) as solvent to give 4 sub-fractions S10A -S10D. Fraction S10C was subjected to semi-preparative HPLC with CH 3 CN-H 2 O (30:70, v/v; 4 mL/min) to afford compound 9 (t R = 24 min; 26 mg) and a subfraction (t R = 4 min) that was separated by semi-preparative HPLC with CH 3 OH-H 2 O (31:69, v/v; 3 mL/min) to afford compounds 11 (t R = 40 min; 11 mg) and 18 (t R = 44 min; 8 mg). Compound 7 (3.3 g) was precipitated from the methanol solution of fraction S15. The remaining sub-fraction of S15 was further subjected to CC over ODS eluted with CH 3 OH-H 2 O (28:72, v/v) to give a sub-fraction that was separated by semi-preparative HPLC with CH 3 CN-H 2 O (11:89, v/v; 5 mL/min) to afford compounds 16 (t R = 16 min; 9 mg) and 12 (t R = 24 min; 80 mg). 
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